BridgeBio Pharma Retained Earnings (Accumulated Deficit) 2018-2024 | BBIO
BridgeBio Pharma retained earnings (accumulated deficit) from 2018 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- BridgeBio Pharma retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $-2.669B, a 20.49% increase year-over-year.
- BridgeBio Pharma retained earnings (accumulated deficit) for 2023 were $-2.561B, a 33.49% increase from 2022.
- BridgeBio Pharma retained earnings (accumulated deficit) for 2022 were $-1.918B, a 33.49% increase from 2021.
- BridgeBio Pharma retained earnings (accumulated deficit) for 2021 were $-1.437B, a 61.68% increase from 2020.
BridgeBio Pharma Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-2,561 |
| 2022 |
$-1,918 |
| 2021 |
$-1,437 |
| 2020 |
$-889 |
| 2019 |
$-440 |
| 2018 |
$-179 |
| 2017 |
$ |
BridgeBio Pharma Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$-2,669 |
| 2024-03-31 |
$-2,596 |
| 2023-12-31 |
$-2,561 |
| 2023-09-30 |
$-2,392 |
| 2023-06-30 |
$-2,215 |
| 2023-03-31 |
$-2,057 |
| 2022-12-31 |
$-1,918 |
| 2022-09-30 |
$-1,781 |
| 2022-06-30 |
$-1,643 |
| 2022-03-31 |
$-1,633 |
| 2021-12-31 |
$-1,437 |
| 2021-09-30 |
$-1,290 |
| 2021-06-30 |
$-1,134 |
| 2021-03-31 |
$-1,038 |
| 2020-12-31 |
$-889 |
| 2020-09-30 |
$-769 |
| 2020-06-30 |
$-653 |
| 2020-03-31 |
$-532 |
| 2019-12-31 |
$-440 |
| 2019-09-30 |
$-367 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$5.045B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
